Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intranasal Ketamine for Uncontrolled Cancer Pain
NCT03146806Phase 2Completed
- Sponsor
- Emory University
- Start
- Jul 2017
- Primary completion
- Apr 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ketamine in cancer pain, sponsored by Emory University. Primary endpoints: Bioavailability of Ketamine up to 4 weeks, Peak Concentration of Ketamine up to 4 weeks and 17 more. Started Jul 2017; status: completed.
02
Drugs
ketamine
03
Conditions
cancer pain
Beyond the preview
Go deeper on NCT03146806.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03146806.